Tag: focus

As Bitcoin returns to the $100,000 mark and global demand for clean energy and remote computing services continues to grow, Find Mining, a long-established cloud mining platform founded in 2018, announced that it has officially launched a new one-stop multi-currency AI cloud mining solution and supporting mobile applications, committed to providing global users with a smarter, low-threshold, and sustainable way to increase the value of digital assets.

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee’s acceptance of employment with Anika as a component of the grantee’s employment compensation.

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space.

DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in connection with their employment. The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individuals entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).